BiomX Inc. Reports Q1 2025 Progress and Financials

Biomx Inc. ( (PHGE) ) has released its Q1 earnings. Here is a breakdown of the information Biomx Inc. presented to its investors.

BiomX Inc., a clinical-stage biotechnology company, is pioneering the development of phage therapies aimed at targeting harmful bacteria to treat chronic diseases. In its first quarter of 2025, BiomX reported significant progress in its clinical programs, notably the positive results from the Phase 2 trial of BX211 for diabetic foot osteomyelitis and the ongoing development of BX004 for cystic fibrosis. The company’s financials showed a net loss reduction to $7.7 million from $17.3 million in the previous year, supported by recent financing that extends its operational runway into 2026. BiomX’s strategic focus remains on advancing its BX004 program, with anticipated Phase 2b results expected in early 2026, reflecting a promising outlook for its innovative bacteriophage therapies.